Mednet Logo
SpecialtiesHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · CompHealth

Venetoclax + CD19 or CD22 mab if available

Would you irradiate all borderline suspicious lymph node regions on PET/CT in stage IIA nodular lymphocyte predominant Hodgkin's lymphoma treated with ISRT alone?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic Florida

ISRT fields for lymphocyte predominant HL when treating without chemotherapy should be more generous in the nodal chain region than if treated with chemotherapy. We conducted a survey of expert lymphoma radiation oncologists published in the IJROBP, which demonstrated some differences in opinion. Ho...

What is the best treatment volume and dose for a marginal zone orbital lymphoma?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

It would depend on the location- retrobulbar, conjunctival or lacrimal gland. Imaging, including MRI, helps in evaluating the site of origin and extent of involvement. Some advocate treating the entire orbit for all orbital lymphomas to be comprehensive, as the total dose is low, and this away we av...

How do you follow patients after radiation treatment for orbital MALT lymphoma?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Local control is extraordinarily high after definitive RT (24 Gy) for orbital MALT lymphoma (>95%). It is not uncommon for patients with retro-orbital disease to have residual masses after RT that remain stable during follow-up. One should be cautious about pursuing additional therapy for presumed "...

Would you require biopsy of both orbits or is unilateral biopsy adequate for a patient with suspected bilateral orbital MALT lymphoma?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Biopsy of one orbit is sufficient if clinical findings and images of the other orbit are all consistent with marginal zone lymphoma (MZL). I’m a little surprised the question of how to treat bilateral MZL of orbit was not asked. Assuming disease is limited to the orbits, radiotherapy to both sites w...

What is your approach to management of chronic neutropenia in a patient with Sjogren’s who was recently diagnosed with metastatic endometrial cancer and plans to start chemotherapy?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University of California, Berkeley and San Francisco

With metastatic cancer, optimal treatment of the endometrial cancer is the priority. Heme/Onc consultant would likely be giving granulocyte stimulating products.Although neutropenia can occur in Sjogren's Disease (SjD), I rarely have found it to be clinically significant, and lymphopenia seems to oc...

Do you discontinue or adjust azathioprine when a patient develops elevated MCV after starting it?

3
2 Answers

Mednet Member
Mednet Member
Rheumatology · Emory University

Great question, with practical implications for the clinic: Azathioprine (AZA) is a prodrug that likely exerts its immunosuppressive effects against B- and T-cell function by interfering with purine metabolism through its metabolites (including 6-MP). Logically, many of the "classic" AZA side effect...

How do you approach the treatment of drug-induced thrombotic microangiopathy?

1 Answers

Mednet Member
Mednet Member
Hematology · Dana-Farber Cancer Institute

Typically, transplant-related TMA is due to sirolimus, tacrolimus, cyclosporine, or some combination of those drugs. The first step is to reduce the dose. Often keeping the drug at the lower end of the therapeutic level, the TMA will resolve or ameliorate. If, for instance, sirol and tac are used to...

How do you treat primary refractory diffuse large B cell lymphoma in elderly patients with good performance status?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Jacksonville

In general, age (by itself) is not a limitation for most of the available therapies for DLBCL elderly patients. Comorbidities and performance status are what drive the decision of what to use as next therapy. I usually recommend all the approved therapies for RR DLBCL. My limit for autologous transp...

When can abdominal surgery be safely performed for presumptive ovarian cancer in a patient with recent pulmonary emboli?

2
1 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

In general, the standard approach is to try to wait as long as possible after the thrombotic event, at the very least three months. This may not be possible, we then reduce that time interval to one month. Given the urgent nature of the surgical intervention, one approach is to wait one month and co...